It is apDia's main concern to be able to offer innovative, advanced and practical diagnostic immunoassays that stand out by their speed, excellent performance, impressive sensitivity and user friendliness.
All research activities within apDia aim to establish this for various domains and applications in human diagnostics. Since the availability of highly specific biomarkers is of utmost importance in achieving improved diagnostic assays, apDia is also exploring the possibilities to identify novel markers for certain diseases.
Well-characterised, good quality and standardized basic reagents are another prerequisite for the reliable performance of an immunoassay. Therefore, apDia is committed to designing, developing and producing its own biological raw materials.
Research projects within apDia involve:
- the development of rapid diagnostic assays
- the development of more sensitive diagnostic assays
- the identification and selection of specific biomarkers:
- Search for more specific markers in oncology and inflammation
- Search for specific markers in autoimmune diseases
- Search for specific markers in psychiatric disorders
- cell culture
- design and development of recombinant antigens
- purification of proteins
apDia has participated / is participating in a number of research projects funded by the EU:
- MOODINFLAME – Early diagnosis, treatment and prevention of mood disorders targeting the activated inflammatory response system (EU 2008-2013)
- EMTICS – European Multicentre Tics in Children Studies (EU 2011-2017)
- PSYCH-AID - Advanced Immuno-neuro-endocrine Diagnostics in Psychiatric Disorders (EU IAPP 2012-2016)
- r'BIRTH - Brain Imaging Return to Health (EU ITN 2013-2017)